Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.
Novartis Pharma AG, Basel, Switzerland.
Clin Trials. 2024 Aug;21(4):399-411. doi: 10.1177/17407745241251568. Epub 2024 Jun 2.
There has been a growing interest in covariate adjustment in the analysis of randomized controlled trials in past years. For instance, the US Food and Drug Administration recently issued guidance that emphasizes the importance of distinguishing between conditional and marginal treatment effects. Although these effects may sometimes coincide in the context of linear models, this is not typically the case in other settings, and this distinction is often overlooked in clinical trial practice. Considering these developments, this article provides a review of when and how to use covariate adjustment to enhance precision in randomized controlled trials. We describe the differences between conditional and marginal estimands and stress the necessity of aligning statistical analysis methods with the chosen estimand. In addition, we highlight the potential misalignment of commonly used methods in estimating marginal treatment effects. We hereby advocate for the use of the standardization approach, as it can improve efficiency by leveraging the information contained in baseline covariates while remaining robust to model misspecification. Finally, we present practical considerations that have arisen in our respective consultations to further clarify the advantages and limitations of covariate adjustment.
近年来,人们对随机对照试验分析中的协变量调整越来越感兴趣。例如,美国食品和药物管理局最近发布了一份指南,强调了区分条件和边缘治疗效果的重要性。虽然这些效果在线性模型的背景下有时可能会重合,但在其他情况下通常并非如此,而且这种区别在临床试验实践中经常被忽视。考虑到这些发展,本文回顾了何时以及如何使用协变量调整来提高随机对照试验的精度。我们描述了条件和边缘估计量之间的区别,并强调了将统计分析方法与所选估计量保持一致的必要性。此外,我们还强调了在估计边缘治疗效果时常用方法可能存在的不匹配。因此,我们提倡使用标准化方法,因为它可以通过利用基线协变量中包含的信息来提高效率,同时保持对模型误设的稳健性。最后,我们提出了在我们各自的咨询中出现的实际考虑因素,以进一步澄清协变量调整的优点和局限性。